Botulinum toxin type A: Exploring new indications

Drugs of Today

Volumn 46, Issue 9, 2010, Pages 671-682

  Brashear, Allison ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN;

ANUS FISSURE; ARTHRITIS; BLEPHAROSPASM; BRUXISM; CERVICAL DYSTONIA; CLOSTRIDIUM BOTULINUM; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ESOPHAGUS ACHALASIA; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HEADACHE; HEMIFACIAL SPASM; HIP PAIN; HUMAN; LOW DRUG DOSE; MIGRAINE; MUSCLE SPASM; MYOFASCIAL PAIN; NONCARDIAC CHEST PAIN; OROMANDIBULAR DYSTONIA; OVERACTIVE BLADDER; PAIN; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PLANTAR FASCIITIS; POSTHERPETIC NEURALGIA; PRESYNAPTIC NERVE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; SPASTICITY; STOMACH PARESIS; TENNIS ELBOW; TRIGEMINUS NEURALGIA; URODYNAMICS; VISUAL ANALOG SCALE; XEROSTOMIA;

BOTULINUM TOXINS, TYPE A; ESOPHAGEAL ACHALASIA; HEADACHE; HUMANS; MALE; PROSTATIC HYPERPLASIA; URINARY BLADDER, OVERACTIVE;

EID: 79955902288     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.9.1524356     Document Type: Review

References (70)

1. Scott, A.B., Rosenbaum, A., Collins, C.C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973, 12(12): 924-7.
2. Scott, A.B., Magoon, E.H., McNeer, K.W., Stager, D.R. Botulinum treatment of strabismus in children. Trans Am Ophthalmol Soc 1989, 87: 174-80.
3. Scott, A.B., Kraft, S.P. Botulinum toxin injection in the management of lateral rectus paresis. Ophthalmology 1985, 92(5): 676-83. (Pubitemid 15060982)
4. Jankovic, J. Blepharospasm and oromandibular-laryngealcervical dystonia: A controlled trial of botulinum A toxin therapy. Adv Neurol 1988, 50: 583-91.
5. Jankovic, J., Brin, M.F. Therapeutic uses of botulinum toxin. N Engl J Med 1991, 324(17): 1186-94.
6. Consensus panel considers uses of botulinum toxin. Clin Pharm 1991, 10(2): 88.
7. Brashear, A., Gordon, M.F., Elovic, E. et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 347(6): 395-400.
8. Childers, M.K., Brashear, A., Jozefczyk, P. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004, 85(7): 1063-9. (Pubitemid 38962361)
9. Elovic, E.P., Brashear, A., Kaelin, D., Liu, J., Millis, S.R., Barron, R., Turkel, C. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008, 89(5): 799-806. (Pubitemid 351602250)
10. FDA Botox approval, July 19, 2010.
11. Hatheway, C.L. Botulism: The present status of the disease. Curr Top Microbiol Immunol 1995, 195: 55-75.
12. Brashear, A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist 2008, 14(5): 289-98.
13. Setler, P.E. Therapeutic use of botulinum toxins: Background and history. Clin J Pain 2002, 18(Suppl. 6): S119-24.
14. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm. 2009. 10-3-0009.
15. Foster, K.A. The analgesic potential of clostridial neurotoxin derivatives. Expert Opin Investig Drugs 2004, 13(11): 1437-43.
16. Aoki, K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43(Suppl. 1): S9-15.
17. Johnstone, S.J., Adler, C.H. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm. Headache 1998, 38(5): 366-8. (Pubitemid 28268607)
18. Binder, W.J., Brin, M.F., Blitzer, A., Schoenrock, L.D., Pogoda, J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg 2000, 123(6): 669-76.
19. Burstein, R., Dodick, D., Silberstein, S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon 2009, 54(5): 624-7.
20. Eross, E.J., Gladstone, J.P., Lewis, S., Rogers, R., Dodick, D.W. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005, 45(4): 308-14. (Pubitemid 40530194)
21. Silberstein, S., Mathew, N., Saper, J., Jenkins, S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000, 40(6): 445-50. (Pubitemid 30421875)
22. Silberstein, S.D., Stark, S.R., Lucas, S.M., Christie, S.N., Degryse, R.E., Turkel, C.C. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80(9): 1126-37.
23. Dodick, D.W. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: From bench to bedside. Headache 2003, 43(Suppl. 1): S25-33.
24. Dodick, D.W., Aurora, S.K., Turkel, C.C. et al. Botulinum neurotoxin type A for treatment of chronic migraine: Double-blind, randomized, placebo-controlled preempt trials. Cephalalgia 2009, 29(12): 1350.
25. UK approval for migraines, 2010.
26. Foster, K.A. A new wrinkle on pain relief: Re-engineering clostridial neurotoxins for analgesics. Drug Discov Today 2005, 10(8): 563-9. (Pubitemid 40544798)
27. Pickett, A. Re-engineering clostridial neurotoxins for the treatment of chronic pain: Current status and future prospects. BioDrugs 2010, 24(3): 173-82.
28. Ranoux, D., Attal, N., Morain, F., Bouhassira, D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008, 64(3): 274-83.
29. Allam, N., Brasil-Neto, J.P., Brown, G., Tomaz, C. Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 2005, 21(2): 182-4. (Pubitemid 40280233)
30. Ngeow, W.C., Nair, R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 109(3): e47-50.
31. Turk, U., Ilhan, S., Alp, R., Sur, H. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005, 28(4): 161-2. (Pubitemid 41134241)
32. Zuñiga, C., Diaz, S., Piedimonte, F., Micheli, F. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr 2008, 66(3A), 500-3.
33. Liu, H.T., Tsai, S.K., Kao, M.C., Hu, J.S. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med 2006, 7(1): 89-91. (Pubitemid 43337716)
34. Ruiz, H.C., Bermejo, P.E. Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia. Neurologie 2008, 23(4): 259-62. (Pubitemid 351897953)
35. Sotiriou, E., Apalla, Z., Panagiotidou, D., Ioannidis, D. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol 2009, 89(2): 214-5.
36. Luvisetto, S., Marinelli, S., Cobianchi, S., Pavone, F. Antiallodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007, 145(1): 1-4. (Pubitemid 46227737)
37. Cheshire, W.P., Abashian, S.W., Mann, J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994, 59(1): 65-9. (Pubitemid 24311170)
38. Gobel, H., Heinze, A., Reichel, G., Hefter, H., Benecke, R., Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain 2006, 125(1-2): 82-8.
39. Foster, L., Clapp, L., Erickson, M., Jabbari, B. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001, 56(10): 1290-3. (Pubitemid 32455285)
40. Gasser, T., Fritsch, K., Arnold, G., Oertel, W. Botulinum toxin A in orthopaedic surgery. Lancet 1991, 338(8769): 761.
41. Boon, A.J., Smith, J., Dahm, D.L. et al. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: A pilot study. PM. R. 2010, 2(4): 268-76.
42. Hadley, H.S., Wheeler, J.L., Petersen, S.W. Effects of intraarticular botulinum toxin type A (Botox(R)) in dogs with chronic osteoarthritis. Vet Comp Orthop Traumatol 2010, 23(4): 254-8.
43. Santamato, A., Ranieri, M., Panza, F. et al. Botulinum toxin type A in the treatment of painful adductor muscle contracture after total hip arthroplasty. Orthopedics 2009, 32(10): pii.
44. Basciani, M., Intiso, D., Cioffi, R.P., Tonali, P. Preoperative treatment with botulinum A toxin in patients with cervical disk herniation secondary to dystonlc cerebral palsy. Neurol Sci 2000, 21(1): 63. (Pubitemid 30430858)
45. Autti-Ramo, I., Larsen, A., Peltonen, J., Taimo, A., von Wendt, L. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics 2000, 31(1): 4-8. (Pubitemid 30172978)
46. Ma, J., Shen, J., Smith, B.P., Ritting, A., Smith, T.L., Koman, L.A. Bioprotection of tendon repair: Adjunctive use of botulinum toxin A in Achilles tendon repair in the rat. J Bone Joint Surg Am 2007, 89(10): 2241-9. (Pubitemid 47606172)
47. Seyler, T.M., Smith, B.P., Marker, D.R. et al. Botulinum neurotoxin as a therapeutic modality in orthopaedic surgery: More than twenty years of experience. J Bone Joint Surg Am 2008, 90(Suppl. 4): 133-45.
48. Bertoni, M., Castagna, A., Baricich, A., Berti, G., Lazzaretti, S., Morandi, C. Administration of type A botulinum toxin after total hip replacement. Eur J Phys Rehabil Med 2008, 44(4): 461-5.
49. Lin, Y.C., Tu, Y.K., Chen, S.S., Lin, I.L., Chen, S.C., Guo, H.R. Comparison between botulinum toxin and corticosteroid injection in the treatment of acute and subacute tennis elbow: A prospective, randomized, double-blind, active drug-controlled pilot study. Am J Phys Med Rehabil 2010, 89(8): 653-9.
50. Babcock, M.S., Foster, L., Pasquina, P., Jabbari, B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: A short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil 2005, 84(9): 649-54. (Pubitemid 41248456)
51. Wang, L., Li, Y.M., Li, L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig Dis Sci 2009, 54(11): 2303-11.
52. Pasricha, P.J., Ravich, W.J., Hendrix, T.R., Sostre, S., Jones, B., Kalloo, A.N. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995, 332(12): 774-8.
53. Pasricha, P.J., Rai, R., Ravich, W.J., Hendrix, T.R., Kalloo, A.N. Botulinum toxin for achalasia: Long-term outcome and predictors of response. Gastroenterology 1996, 110(5): 1410-5.
54. Walzer, N., Hirano, I. Achalasia. Gastroenterol Clin North Am 2008, 37(4): 807-25, viii.
55. Miller, L.S., Parkman, H.P., Schiano, T.D. et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 1996, 41(10): 2025-31. (Pubitemid 26366804)
56. Miller, L.S., Pullela, S.V., Parkman, H.P., Schiano, T.D., Cassidy, M.J., Cohen, S., Fisher, R.S. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol 2002, 97(7): 1640-6. (Pubitemid 34761383)
57. Bashashati, M., Andrews, C., Ghosh, S., Storr, M. Botulinum toxin in the treatment of diffuse esophageal spasm. Dis Esophagus 2010, Epub ahead of print.
58. Storr, M., Allescher, H.D., Classen, M. Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm. Drugs 2001, 61(5): 579-91. (Pubitemid 32453370)
59. Maria, G., Cassetta, E., Gui, D., Brisinda, G., Bentivoglio, A.R., Albanese, A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med 1998, 338(4): 217-20. (Pubitemid 28047574)
60. Bai, Y., Xu, M.J., Yang, X., Xu, C., Gao, J., Zou, D.W., Li, Z.S. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion 2010, 81(1): 27-34.
61. Lee, S.J., McCall, W.D. Jr., Kim, Y.K., Chung, S.C., Chung, J.W. Effect of botulinum toxin injection on nocturnal bruxism: A randomized controlled trial. Am J Phys Med Rehabil 2009. Epub ahead of print.
62. Lang, R., White, P.J., Machalicek, W. et al. Treatment of bruxism in individuals with developmental disabilities: A systematic review. Res Dev Disabil 2009, 30(5): 809-18.
63. Sellers, D. J., McKay, N. Developments in the pharmacotherapy of the overactive bladder. Curr Opin Urol 2007, 17(4): 223-30.
64. Brin, M. F. Development of future indications for BOTOX. Toxicon 2009, 54(5): 668-74.
65. Anger, J.T., Weinberg, A., Suttorp, M.J., Litwin, M.S., Shekelle, P.G. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: A systematic review of the literature. J Urol 2010, 183(6): 2258-64.
66. Flynn, M.K., Webster, G.D., Amundsen, C.L. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 2004, 172(6 Pt. 1): 2316-20. (Pubitemid 39507517)
67. Flynn, M.K., Amundsen, C.L., Perevich, M., Liu, F., Webster, G.D. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009, 181(6): 2608-15.
68. Kessler, T.M., Khan, S., Panicker, J., Roosen, A., Elneil, S., Fowler, C.J. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: Short-term effect on quality of life. Obstet Gynecol 2009, 113(5): 1046-51.
69. Maria, G., Brisinda, G., Civello, I.M., Bentivoglio, A.R., Sganga, G., Albanese, A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 2003, 62(2): 259-64. (Pubitemid 36952073)
70. Kuo, H.C., Liu, H.T. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009, 43(3): 206-11.